Skip to content
Login
Search:
CROI Conference
CROI ConferenceCROI Conference
  • About CROI
    • CROI 2027 Important Dates
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • CROI Abstract Categories
    • Abstract Guidelines and Submission
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Who Can Attend
    • Letter Of Invitation (For Visa And Other Purposes)
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
  • Program
    • CROI 2027 Program
    • Our Voices
    • Media
    • Embargo Policies And Press Release Policies
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • About CROI
    • CROI 2026 Preliminary Important Dates and Deadlines
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • Abstract Guidelines and Submission
    • CROI Abstract Categories
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Oral Abstract Presentation Guidelines
    • Poster Presentation Guidelines
    • Themed Discussion Guidelines
    • Plain Language Summaries: A Mile-High View at CROI 2026
    • People-First Language and the Use of Appropriate Terminology
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Registration
    • Who Can Attend
    • Media Accreditation and Registration
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
    • Scholarship Travel
  • Program
    • CROI 2027 Program
    • CROI 2026 Resources
    • Our Voices
    • Media
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • CROI 2027 Important Dates

Search Results for: node/PEP: Remember Me?

1275 – Postexposure Prophylaxis With Doxycycline (Doxy PEP) in a Cohort of High-Risk MSM: The PRIDOX Study

By Jimmy He PharmD, DScMarch 20, 2025

…DoxyPEP trials, were offered DoxyPEP. This analysis includes PrEP users who initiated DoxyPEP between March/23 and August/24. The pre-DoxyPEP period was from PrEP initiation to DoxyPEP beginning, and the post-DoxyPEP…

Sustained Reduction of Bacterial STIs During the DoxyPEP Study Open-Label Extension

By Jimmy He PharmD, DScApril 26, 2024

…uptake, adherence, sexual activity, and incident bacterial STIs, as awareness of STI prevention efficacy may impact patterns of doxy-PEP use and sexual behavior. Methods: DoxyPEP is an open-label trial conducted…

Management of Acute HIV After Initiation of Postexposure Prophylaxis: Challenges and Lessons Learnt

By Enthusiast Inc MDFebruary 27, 2015

Background: International guidelines recommend HIV post exposure prophylaxis following sexual exposure (PEPSE) to prevent HIV infection. However, methods to screen for infection prior to initiating PEPSE are less clear, with…

Management of Acute HIV After Initiation of Postexposure Prophylaxis: Challenges and Lessons Learnt

By Enthusiast Inc MDFebruary 27, 2015

Background: International guidelines recommend HIV post exposure prophylaxis following sexual exposure (PEPSE) to prevent HIV infection. However, methods to screen for infection prior to initiating PEPSE are less clear, with…

1319 – Uptake of Online HIV PrEP and PEP in Kenya After Removal of Subsidies: A Pilot Extension Study

By Jimmy He PharmD, DScApril 18, 2025

…a challenge, but high demand for online PEP and low transitions from PEP to PrEP suggest opportunities to expand access to PEP, which has been underutilized in HIV prevention efforts. …

1035 – DoxyPEP Uptake Among Male US Veterans Diagnosed With Bacterial STIs: A Cohort Study, 2022-2025

By Jimmy He PharmD, DScMarch 31, 2026

…for doxyPEP. We evaluated doxyPEP use by age, race, HIV status, pre-exposure prophylaxis (PrEP) use, and region using multivariate logistic regression. We evaluated time to doxyPEP after an index STI…

1047 – Impact of Doxycycline Postexposure Prophylaxis on Antibiotic Use at a Boston Sexual Health Clinic

By Jimmy He PharmD, DScMarch 31, 2026

…DPEP, and the proportion of current DPEP users who had newly started DPEP at a given time step.  Results Among 1465 patients who met our inclusion criteria, 939 started DPEP…

POTENTIAL IMPACT AND EFFICIENCY OF DOXY-PEP AMONG PEOPLE WITH OR AT RISK OF HIV

By Jimmy He PharmD, DScMarch 24, 2023

…patients who met each criterion were prescribed doxy-PEP indefinitely (strategies 1–3) or for 12m (strategies 4–10). We assumed STI incidence during doxy-PEP use would have been reduced by clinical trial…

1323 – nPEP When You Need It: A 24/7 Post-Exposure Prophylaxis Hotline in the District of Columbia

By Jimmy He PharmD, DScMarch 20, 2025

…ethnically, 17.1% identified as Latino. 78.6% of the nPEP users identified as cisgender men, 18.7% as cisgender women, 1.4% as transgender women, 0.3% as transgender men and 1.0% as genderqueer. …

DEFINING IMMUNOGENIC PEPTIDES TARGETING SARS-CoV-2 VARIANTS OF CONCERN

By Jimmy He PharmD, DScApril 4, 2022

Identifying Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2) specific T-cell epitope-derived peptides that are also found within variants of concern (VOC) is critical for measuring the duration of cellular…

←12345…
678910111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970717273747576777879808182
83→
Copyright © 2026 CROI Foundation/IAS-USA. All Rights Reserved.
Website by Enthusiast, Inc.
  • About CROI
  • Presenters
  • Abstracts
  • Scholarships
  • Program
Footer Menu
Go to Top